ArticleCureus2026
Identifying Flare Prone Spondyloarthritis: Insights From a Prospective Cohort.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Flares are episodes of disease worsening requiring a change in treatment. Incidence of flares in spondyloarthritis (SpA) is around 60% in longitudinal patient-reported studies. The study was conducted to determine characteristics of flares in SpA and to identify differences between flare and non-flare populations. We hypothesized that the patient cohort who develop flares may behave differently in terms of validated disease activity and functional indices with regard to the non-flare population. Methods A cohort of 106 patients (2650 patient-weeks follow-up and 318 visits) who fulfilled the European Spondyloarthropathy Study Group (ESSG) or Assessment of SpondyloArthritis International Society (ASAS) classification criteria for SpA were followed up for six months. Diagnosis of flare was made by the rheumatologist using patient-reported indices and ruling out confounders. Statistical methods for analysis include the Mann-Whitney U test, ANOVA, chi-square, survival analyses, and longitudinal analyses by mixed-effects models, repeated measures ANOVA. Results At six months, 67 of 106 patients (63.2%) developed flares, of whom 51 (76.1%) had major (generalized) flares, and 16 (23.9%) had minor (localized) flares. In univariable analyses, shorter disease duration (<6 years), baseline enthesitis, baseline glucocorticoid use, and higher baseline disease activity were associated with increased odds of flare, whereas radiographic axial SpA was associated with reduced odds. In multivariable logistic regression analysis, inactive disease (OR: 0.21; 95% CI: 0.05-0.94; p = 0.042) and low disease activity at baseline (OR: 0.25; 95% CI: 0.09-0.72; p = 0.011) were independently associated with lower odds of flare, while baseline enthesitis was associated with higher odds (OR: 11.29; 95% CI: 1.30-93.46; p = 0.025). The median time to flare was longer in patients receiving biologic or targeted synthetic DMARDs (88 days vs 26 days), although this difference did not reach statistical significance (p = 0.249). Longitudinal analyses using general linear and mixed-effects models demonstrated significant differences in trajectories of ASAS-validated indices between flare and non-flare groups. Conclusion Baseline disease activity and enthesitis status are key determinants of flare risk in SpA. Patients with inactive or low disease activity have lower odds of flare, whereas the presence of enthesitis is associated with increased risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.